Venetoclax

维奈克拉

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameVenetoclax
Drug Alias Name维奈克拉venetoclaxum维奈托克venetoclax维奈妥拉 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmChromosome DeletionLupus Erythematosus, Cutaneous +[34] 
Global Approved IndicationsLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLeukemia, Myeloid, Acute
Original Approved Country/TerritoryUnited States
Original Approved Date2016/04/11
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie IncGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstitutePla General HospitalRoche Pharma Ag +[14] 
Inactive CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)Dusa Pharmaceuticals Inc
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesRenal Insufficiency +[23] 
Inactive IndicationsChromosome DeletionLupus Erythematosus, CutaneousKeratosis, Actinic +[11] 

Other Information

ATC CodeL01XX52
Related LinksWikipediaDrugBankKEGG